TB-500
TB-500 is a thymosin β-4 fragment with limited human data. Under FDA review for compounding.
- Routesubcutaneous injection
- Baseline labsNot typically required
- EvidenceLimited human data
- AvailabilityEducation only
How it works
TB-500 is a synthetic version of a fragment of thymosin beta-4, a naturally occurring peptide found throughout the body that plays roles in cell migration, actin regulation (part of the cell's internal scaffolding), and tissue organization. In preclinical models it has been studied in the context of wound healing, angiogenesis, and recovery, often discussed alongside BPC-157 in the 'repair' category.
As with BPC-157, the honest headline is that the research base is mostly preclinical. The biology of thymosin beta-4 is real and interesting, but extrapolating from animal and laboratory studies of a fragment to human outcomes is a substantial leap, and the controlled human data isn't there to support firm conclusions.
What it's been studied for
- Tissue-repair, cell-migration, and angiogenesis pathways (mostly preclinical)
- Recovery-related markers in animal models
“Studied for” describes what research has examined — not a promise of any outcome for you.
What the evidence says
Human data for this peptide is limited. A licensed provider can discuss what the current evidence does and does not support for you.
What to expect at Clyne
TB-500 is under FDA review for compounding and is education-only here for now. You can join the waitlist to be notified if its status changes.
We'll keep this profile honest as the regulatory picture develops rather than implying availability that doesn't exist.
Safety & considerations
Limited human data means real uncertainty, and a provider can help you weigh that honestly rather than optimistically. The mechanistic story is not a substitute for evidence of benefit in people.
Avoid gray-market sources that sell unregulated vials for non-medical use; purity and identity in that market can't be verified.
Regulatory status
This peptide is currently under FDA review for compounding and is not available to prescribe. It is on the FDA's PCAC agenda (docket FDA-2025-N-6895). A regulatory category that permits compounding is not the same as FDA approval.
Common questions
Is TB-500 the same as thymosin beta-4?
Not exactly. TB-500 is a synthetic fragment related to the active region of thymosin beta-4, not the full natural peptide.
Is it available now?
No — it's under FDA review for compounding and is education-only here. You can join the waitlist for updates.
Join the waitlist
TB-500 isn't currently available. Add your email and we'll notify you if its status changes — no charge, no commitment.